Chemometric methods for the quantification of crystalline tacrolimus in solid dispersion by powder X-ray diffractrometry

Journal of Pharmaceutical Sciences

Volumn 103, Issue 9, 2014, Pages 2819-2828

  Siddiqui, Akhtar ^a   Rahman, Ziyaur ^a   Bykadi, Srikant ^a   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

chemometric; multivariate analysis; partial least square; powder X ray diffraction; principal component analysis; solid dispersion; tacrolimus

Indexed keywords

CROSCARMELLOSE SODIUM; EXCIPIENT; LACTOSE; TACROLIMUS; POWDER;

ARTICLE; CALIBRATION; CHEMOMETRIC ANALYSIS; CHEMOMETRICS; COLOR; DENSITY; DISPERSION; DRUG DOSAGE FORM; PARTICLE SIZE; POLYMERASE CHAIN REACTION; PREDICTION; SIGNAL NOISE RATIO; SOLID DISPERSION; X RAY DIFFRACTION; CHEMISTRY; CRYSTALLIZATION; MEDICINAL CHEMISTRY; NEAR INFRARED SPECTROSCOPY; POWDER; POWDER DIFFRACTION; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; REGRESSION ANALYSIS;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; EXCIPIENTS; LEAST-SQUARES ANALYSIS; POWDER DIFFRACTION; POWDERS; PRINCIPAL COMPONENT ANALYSIS; SPECTROSCOPY, NEAR-INFRARED; TACROLIMUS; X-RAY DIFFRACTION;

EID: 84906311413     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23912     Document Type: Article

References (23)

1. Borhade V, Nair H, Hegde D,. 2008. Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS Pharm Sci Tech 9: 13-21.
2. Letko E, Bhol K, Pinar V, Foster CS, Ahmed AR,. 1999. Tacrolimus (FK 506). Ann Allergy Asthma Immunol 83: 179-190.
3. Yoshida T, Kurimoto I, Yoshihara K, Umejima H, Ito N, Watanabe S, Sako K, Kikuchi A,. 2012. Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: Evaluation of solid dispersion formulations. Int J Pharm 428: 18-24.
4. Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K,. 2001. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 90: 690-701.
5. Wang Y, Zhang T, Liu H, He F, Hegde D,. 2011. Enhanced oral bioavailability of tacrolimus in rats by self-emulsifying drug delivery systems. Drug Dev Ind Pharm 37: 1225-1230.
6. Overhoff K, McConville J, Yang W, Johnston K, Peters J, Williams R,. 2008. Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res 25: 167-175.
7. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S,. 2002. Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 91: 719-729.
8. Pople PV, Singh KK,. 2010. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int J Pharm 398: 165-178.
9. Patel P, Patel H, Panchal S, Mehta T,. 2012. Formulation Strategies for drug delivery of tacrolimus: An overview. Int J Pharm invest 2: 169-175.
10. Staatz C, Tett S,. 2004. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43: 623-653.
11. Borhade VB, Nair HA, Hegde DD,. 2009. Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration. Drug Dev Ind Pharm 35: 619-630.
12. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, Higaki K, Kimura T,. 2003. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 267: 79-91.
13. Joe JH, Lee WM, Park YJ, Joe KH, Oh DH, Seo YG, Woo JS, Yong CS, Choi HG,. 2010. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int J Pharm 395: 161-166.
14. Serajuddin ATM,. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88: 1058-1066.
15. Guo Y, Shalaev E, Smith S,. 2013. Physical stability of pharmaceutical formulations: Solid-state characterization of amorphous dispersions. TrAC Trends Anal Chem 49: 137-144.
16. Liu J, Nagapudi K, Kiang Y-H, Martinez E, Jona J,. 2009. Quantification of compaction-induced crystallinity reduction of a pharmaceutical solid using 19F solid-state NMR and powder X-ray diffraction. Drug Dev Ind Pharm 35: 969-975.
17. Wise BM, Gallagher NB,. 1996. The process chemometrics approach to process monitoring and fault detection. J Process Control 6: 329-348.
18. Siddiqui A, Rahman Z, Sayeed VA, Khan MA,. 2013. Chemometric evaluation of near infrared, Fourier transform infrared, and raman spectroscopic models for the prediction of nimodipine polymorphs. J Pharm Sci 102: 4024-4035.
19. Medicines Evaluation Board (MEB) 2010. Public assessment report of the medicine evaluation board in the Netherlands [tacrolimus Sandoz 0.5 mg, 1 mg, 5 mg, capsules, Hard Sandoz B.V., The Netherlands tacrolimus (as monohydrate)].
20. Medicines Evaluation Board (MEB) 2010. Public assessment report of the medicines evaluation board in the Netherlands [(tacrolimus Accord 0.5 mg and 1mg capsules, hard Accord Healthcare Ltd., United Kingdom tacrolimus (as monohydrate)].
21. Yamashita K, Hashimoto E, Nomura Y, Shimojo F, Tamura S, Hirose T, Ueda S, Saitoh T, Ibuki R, Ideno T,. 2005. Google Patents US Patent No; 6884433 Sustained release formulation containing tacrolimus.
22. SUDA M, Takayama K, Otsuka M,. 2008. An accurate quantitative analysis of polymorphic content by chemometric X-ray powder diffraction. Anal Sci 24: 451-457.
23. Wu Z, Sui C, Xu B, Ai L, Ma Q, Shi X, Qiao Y,. 2013. Multivariate detection limits of on-line NIR model for extraction process of chlorogenic acid from Lonicera japonica. J Pharm Biomed Anal 77: 16-20.